Estrella Immunopharma Activates Oregon Health & Science University as Third Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
Estrella Immunopharma has activated Oregon Health & Science University as the third clinical site for its Phase I/II STARLIGHT-1 trial evaluating EB103 in relapsed or refractory B-cell non-Hodgkin’s lymphoma. The expansion phase aims to evaluate safety and efficacy at the recommended Phase II dose, with data intended to determine the pivotal trial strategy for EB103.
Key figures
- Drug Name
- EB103
- Phase Of Trial
- Phase I/II
- Nct identifier
- NCT06343311
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.